BioSpace News Archive

Researchers say transplanting fecal microbiota from the mother into the newborn can reverse the risk for Type 1 diabetes for babies who had been exposed to antibiotic treatments early.

Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow.

The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.

The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.

Aprea Therapeutics, Inc. today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the novel mechanism of action (MOA) of MCLA-145, the Company’s clinical stage Biclonics® T-cell agonist.

ViaCyte, Inc., an innovator in cellular therapy and regenerative medicine, announced that it has appointed Jon Wilensky, MD, MBA, FACS, as Head of Surgery.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces study results showing patients treated with just its REGENETEN Bioinductive Implant for partial-thickness rotator cuff tears (>3mm) experienced significantly improved shoulder function during early recovery compared to patients receiving a REGENETEN Implant plus traditional surgical repair.

Apollo Medical Holdings, Inc. today announced that it will release financial results for the second quarter and six months ended June 30, 2021, after the close of the stock market on Thursday, August 5, 2021.

IM Therapeutics today announced positive results on safety, tolerability, pharmacokinetics (PK) and mechanistic action in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D).